JP2004505078A5 - - Google Patents

Download PDF

Info

Publication number
JP2004505078A5
JP2004505078A5 JP2002515887A JP2002515887A JP2004505078A5 JP 2004505078 A5 JP2004505078 A5 JP 2004505078A5 JP 2002515887 A JP2002515887 A JP 2002515887A JP 2002515887 A JP2002515887 A JP 2002515887A JP 2004505078 A5 JP2004505078 A5 JP 2004505078A5
Authority
JP
Japan
Prior art keywords
heteroalkyl
hydrogen
compound according
alkyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002515887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505078A (ja
JP3984157B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/008293 external-priority patent/WO2002010158A2/en
Publication of JP2004505078A publication Critical patent/JP2004505078A/ja
Publication of JP2004505078A5 publication Critical patent/JP2004505078A5/ja
Application granted granted Critical
Publication of JP3984157B2 publication Critical patent/JP3984157B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002515887A 2000-07-27 2001-07-18 グリコーゲンシンターゼキナーゼ−3ベータのインヒビターとしての3−インドリル−4−フェニル−1h−ピロール−2,5−ジオン誘導体 Expired - Lifetime JP3984157B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22105800P 2000-07-27 2000-07-27
PCT/EP2001/008293 WO2002010158A2 (en) 2000-07-27 2001-07-18 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta

Publications (3)

Publication Number Publication Date
JP2004505078A JP2004505078A (ja) 2004-02-19
JP2004505078A5 true JP2004505078A5 (cg-RX-API-DMAC7.html) 2005-03-03
JP3984157B2 JP3984157B2 (ja) 2007-10-03

Family

ID=22826151

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002515887A Expired - Lifetime JP3984157B2 (ja) 2000-07-27 2001-07-18 グリコーゲンシンターゼキナーゼ−3ベータのインヒビターとしての3−インドリル−4−フェニル−1h−ピロール−2,5−ジオン誘導体

Country Status (31)

Country Link
US (2) US6479490B2 (cg-RX-API-DMAC7.html)
EP (1) EP1307447B1 (cg-RX-API-DMAC7.html)
JP (1) JP3984157B2 (cg-RX-API-DMAC7.html)
KR (1) KR20030017655A (cg-RX-API-DMAC7.html)
CN (1) CN1185229C (cg-RX-API-DMAC7.html)
AR (1) AR033989A1 (cg-RX-API-DMAC7.html)
AT (1) ATE284885T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001293702A1 (cg-RX-API-DMAC7.html)
BR (1) BR0112965A (cg-RX-API-DMAC7.html)
CA (1) CA2417277A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2003555A3 (cg-RX-API-DMAC7.html)
DE (1) DE60107857T2 (cg-RX-API-DMAC7.html)
EC (1) ECSP034452A (cg-RX-API-DMAC7.html)
ES (1) ES2233691T3 (cg-RX-API-DMAC7.html)
GT (1) GT200100151A (cg-RX-API-DMAC7.html)
HR (1) HRP20030030A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0301431A2 (cg-RX-API-DMAC7.html)
IL (1) IL153851A0 (cg-RX-API-DMAC7.html)
JO (1) JO2293B1 (cg-RX-API-DMAC7.html)
MA (1) MA26936A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03000695A (cg-RX-API-DMAC7.html)
NO (1) NO20030328L (cg-RX-API-DMAC7.html)
NZ (1) NZ523462A (cg-RX-API-DMAC7.html)
PA (1) PA8523001A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020338A1 (cg-RX-API-DMAC7.html)
PL (1) PL366701A1 (cg-RX-API-DMAC7.html)
RU (1) RU2003104796A (cg-RX-API-DMAC7.html)
UY (1) UY26857A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002010158A2 (cg-RX-API-DMAC7.html)
YU (1) YU4403A (cg-RX-API-DMAC7.html)
ZA (1) ZA200300216B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224932A4 (en) * 1999-08-20 2002-10-16 Sagami Chem Res ACTIVE SUBSTANCES TO INHIBIT CELL DEATH
PL366009A1 (en) * 2000-10-02 2005-01-24 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
DE60140201D1 (en) * 2000-11-07 2009-11-26 Novartis Ag Indolylmaleimidderivative als proteinkinase-c-inhibitoren
US6645970B2 (en) * 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
JP2005532982A (ja) * 2001-09-24 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのピロール誘導体の製造及び使用
ES2316756T3 (es) * 2002-01-10 2009-04-16 F. Hoffmann-La Roche Ag Uso de un inhibidor de gsk-3beta en la fabricacion de un medicamento para incrementar la formacion osea.
EP1483265B1 (en) 2002-03-05 2006-11-22 Eli Lilly And Company Purine derivatives as kinase inhibitors
US7405305B2 (en) 2002-03-08 2008-07-29 Eli Lilly And Company Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
CN1671694A (zh) 2002-06-05 2005-09-21 詹森药业有限公司 作为激酶抑制剂的二吲哚基-顺丁烯二酰亚胺衍生物
CA2488798A1 (en) 2002-06-05 2003-12-18 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
US7250444B2 (en) * 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
US7109436B2 (en) * 2003-08-29 2006-09-19 General Electric Company Laser shock peening target
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
EP1682103A1 (en) * 2003-10-27 2006-07-26 Novartis AG Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
CN1949967B (zh) * 2004-05-12 2012-02-01 拜尔作物科学有限公司 植物生长调节作用
CA2589127C (en) 2004-12-08 2013-02-05 Johannes Gutenberg-Universitat Mainz 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
JP4747364B2 (ja) 2005-04-04 2011-08-17 独立行政法人産業技術総合研究所 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
WO2008080824A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Aromatic sulfonated ketals
CA2729259A1 (en) * 2008-06-25 2009-12-30 Envivo Pharmaceuticals, Inc. 1,2-disubstituted heterocyclic compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2012033225A1 (en) 2010-09-08 2012-03-15 Sumitomo Chemical Company, Limited Method for producing pyridazinone compounds and intermediate thereof
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
KR20130034672A (ko) * 2011-09-28 2013-04-08 김동식 보텍스타입 열교환기
KR101440724B1 (ko) * 2013-03-29 2014-09-18 중앙대학교 산학협력단 글리코겐 신타아제 키나아제-3베타 억제물질을 유효성분으로 포함하는 난소과립세포종양의 예방 또는 치료용 약학적 조성물 및 건강기능성식품 조성물
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN112538458B (zh) 2020-11-26 2025-10-31 北京孟眸生物科技有限公司 用于重编程细胞的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89167A (en) * 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
EP0868195A2 (en) 1995-12-20 1998-10-07 Medical Research Council Control of protein synthesis, and screening method for agents
AU2819397A (en) 1996-05-07 1997-11-26 Presidents And Fellows Of Harvard College Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
DE69922526T2 (de) * 1998-10-08 2005-06-02 Smithkline Beecham Plc, Brentford 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds

Similar Documents

Publication Publication Date Title
JP2004505078A5 (cg-RX-API-DMAC7.html)
RU2003104796A (ru) Производные 3-индолил-4-фенил-1н-пиррол-2, 5-диона в качестве ингибиторов гликогенсинтазы-киназы-3 бета
CN1038131C (zh) 吡咯并嘧啶衍生物和其制备中间体及含其的药物组合物和用途
CN1154500C (zh) 1,3-氧硫环戊烷核苷类似物药物组合物的制备方法
KR102118559B1 (ko) 면역-관련 및 염증성 질환의 치료
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2004532240A5 (cg-RX-API-DMAC7.html)
JP2018507877A5 (cg-RX-API-DMAC7.html)
JP2009507909A5 (cg-RX-API-DMAC7.html)
CN1132073A (zh) 含有1,3-氧硫杂环戊烷核苷类似物的药物组合物的制备方法
JP2006507355A5 (cg-RX-API-DMAC7.html)
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
IS2293B (is) Arýl sambrædd asapólýsýklísk efnasambönd
JP2005539088A5 (cg-RX-API-DMAC7.html)
JP2005519932A5 (cg-RX-API-DMAC7.html)
HUT77436A (hu) Purin- és guaninszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására
MX2007007845A (es) Sulfonilpirrolidinas, metodo para producir las mismas y su uso como medicamento.
CA2917965A1 (fr) Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2003115426A (ru) Замещенные производные 2-фениламиноимидазолинфенилкетона в качестве антагонистов ip
JP2004529145A5 (cg-RX-API-DMAC7.html)
ATE479433T1 (de) Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
JP2020502116A5 (cg-RX-API-DMAC7.html)
JP2004507540A5 (cg-RX-API-DMAC7.html)
TNSN07006A1 (en) Novel heterocyclic compounds
JP2005517008A5 (cg-RX-API-DMAC7.html)